Bisbentiamine Encyclopedia — Scientific Background

What Is Bisbentiamine?

Bisbentiamine (CAS 2667-89-2), also known as O-benzoylthiamine disulfide, dibenzoylthiamine, bentiamine, or vitamin B1 disulfide derivative, is a synthetic, lipid-soluble thiamine (vitamin B1) derivative with the molecular formula C₃₈H₄₂N₈O₆S₂ and a molecular weight of 770.92 g/mol. It is chemically characterized as an O-benzoyl thiamine disulfide consisting of two thiamine moieties linked by a disulfide bridge, with benzoyl groups esterified at the O-position. Bisbentiamine occurs as white crystals or a crystalline powder with a melting point of 141–147°C and a purity specification of 98.0–102.0% on the dried basis.

The Lipid-Soluble Advantage Over Water-Soluble Thiamine

Bisbentiamine represents a fundamentally different approach to thiamine supplementation compared to conventional water-soluble thiamine salts. Water-soluble thiamine salts (e.g., thiamine hydrochloride, thiamine nitrate) rely on saturable, rate-limited active transport mechanisms for intestinal absorption. As the dose increases, these transporters become saturated, and absorption efficiency declines.

Bisbentiamine addresses this critical limitation of conventional thiamine salts—poor lipid solubility and carrier-mediated transport saturation. Its disulfide-linked, O-benzoylated structure enables passive membrane diffusion, superior oral bioavailability, and intrinsic resistance to thiaminase degradation. Bisbentiamine is an O-benzoyl thiamine disulfide or vitamin B1 disulfide derivative, and lipid-soluble thiamine precursors such as bisbentiamine have a much higher bioavailability than genuine thiamine and therefore are more suitable for therapeutic purposes.

The LogP of 5.59 ensures passive blood-brain barrier penetration, in contrast to the LogP of ≈−3.0 for thiamine hydrochloride. Bisbentiamine is a lipophilic thiamine prodrug with pH-dependent solubility, and its bioavailability is regulated by diet type, administration time, gastric acidity, and formulation.

Mechanisms of Action

Conversion to Active Thiamine Diphosphate (TDP)

Bisbentiamine is a prodrug that is converted to active thiamine (vitamin B1) in the body after oral absorption. Following oral administration, bisbentiamine is absorbed and converted to free thiamine, which is then phosphorylated to thiamine diphosphate (TDP), the active cofactor form of vitamin B1. TDP is required for the activity of transketolase in the pentose phosphate pathway, pyruvate dehydrogenase in carbohydrate metabolism, and alpha-ketoglutarate dehydrogenase in the TCA cycle. These enzymatic reactions are essential for cellular energy production, particularly in nerve tissue which has high energy demands.

Nerve Conduction and Neuroprotective Mechanisms

Bisbentiamine increases pain suppression in the dorsal spine and decreases cerebral nerve responses to pain. It is indicated for neuralgia, muscle pain, joint pain, peripheral neuritis, and peripheral nerve palsy, demonstrating its therapeutic potential for neurological conditions. Bisbentiamine has also been investigated for its role in relieving shoulder stiffness and lower back pain, supporting its use in musculoskeletal and neurological applications.

Thiaminase Resistance and Stability

Bisbentiamine is intrinsically resistant to thiaminase degradation, making it stable in biological systems where thiaminase enzymes would otherwise destroy water-soluble thiamine. This resistance ensures that the active thiamine moieties reach target tissues intact and are efficiently converted to active TDP.

The Bioavailability Challenge

Despite its advantages over water-soluble thiamine, native bisbentiamine presents formulation challenges. The compound has pH-dependent solubility, dissolving readily in acidic environments and poorly at neutral pH, which affects its dissolution rate and absorption. Bioavailability of bisbentiamine is regulated by diet type, administration time, gastric acidity, and formulation, and the extent and rate of bioavailability decrease significantly on preprandial administration and tend to decrease with postprandial administration, as compared to administration between meals and during fasting.

liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects bisbentiamine during digestive transit and enhances aqueous dispersibility. Liposomal delivery systems ensure greater absorption and bioavailability of active substances due to the added value of the liposomal carrier, compared to free and other conventional pharmaceutical carriers including tablets, suspensions, and capsules.

Liposomal Bisbentiamine

Liposomal encapsulation of bisbentiamine provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the bisbentiamine molecule, forming a protective shell that enhances stability, dispersibility, and cellular uptake. This delivery system:

• Protects bisbentiamine from pH-induced precipitation in the neutral-to-alkaline environment of the small intestine

• Transforms poorly water-soluble bisbentiamine into a water-dispersible powder

• Enhances cellular uptake through membrane fusion and lipid-mediated pathways

• Provides sustained release for prolonged elevation of intracellular TDP levels

• Complements bisbentiamine‘s intrinsic blood-brain barrier penetration capability

Clinical Evidence

Thiamine Deficiency and Wernicke’s Encephalopathy

Bisbentiamine is indicated for prevention and treatment of vitamin B1 deficiency, Wernicke’s encephalopathy, and beriberi, as well as when vitamin B1 deficiency or metabolic disorder is involved in neuralgia, muscle pain, joint pain, peripheral neuritis, and peripheral nerve palsy. Lipid-soluble thiamine precursors such as bisbentiamine have cured many patients with vitamin B1 deficiency resulting in beriberi neuropathy and Wernicke‘s encephalopathy.

Comparative Blood Concentration Study

A comparative study evaluated changes in blood concentration, urine excretion, and enzyme levels after intravenous injection of bisbentiamine compared to thiamine hydrochloride. The results showed that bisbentiamine had higher and more sustained blood concentrations than thiamine hydrochloride, but a lower urinary excretion rate, indicating greater retention of the active vitamin in the body.

Diet and Bioavailability Interactions

A pharmacokinetic study systematically investigated the effects of diet intake on the bioavailability of experimental tablets and suspension containing bisbentiamine by measuring urinary thiamine excretion in humans. The study demonstrated that the extent and rate of bioavailability decreased significantly on preprandial administration and also tended to decrease in postprandial conditions as compared to administration between meals and fasted conditions. These findings support the clinical recommendation to take bisbentiamine after meals for optimal absorption.

Pharmacokinetic Profile

Bisbentiamine is rapidly absorbed after oral administration. Bisbentiamine produces a lower initial plasma spike of free thiamine compared to intravenous thiamine, but maintains a sustained release due to a reservoir effect in erythrocytes. This sustained-release pharmacokinetic profile is particularly advantageous for nerve tissue, which requires continuous thiamine availability for Energy Metabolism and nerve conduction.

Diabetic Neuropathy

Bisbentiamine is a scientifically compelling candidate for the treatment of diabetic neuropathy. By leveraging an enhanced pharmacokinetic profile, bisbentiamine may offer therapeutic benefits for pre-diabetes and early-stage neuropathy, potentially preventing irreversible nerve damage.

Safety and Regulatory

Bisbentiamine has a favorable safety profile. In clinical use, no severe adverse events have been reported. Bisbentiamine is classified as a third-class OTC drug in Japan, indicating a well-established safety profile for over-the-counter use. The Japanese Pharmacopoeia specifies that bisbentiamine, when dried, contains 98.0–102.0% of C₃₈H₄₂N₈O₆S₂, ensuring pharmaceutical-grade quality and purity.

Regulatory Status:

• Japan — Bisbentiamine is approved as a pharmaceutical ingredient (JAN/INN) and is classified as a third-class OTC drug. It is available under the brand name Beston for vitamin B1 supplementation and treatment of thiamine deficiency-related conditions.

• Taiwan — Bisbentiamine is available in combination products with other B vitamins for neuritis, polyneuritis, beriberi, and vitamin B1 deficiency-related conditions.

• Global Standards — Bisbentiamine is monographed in the Japanese Pharmacopoeia with a purity specification of 98.0–102.0%. The product is available with pharmaceutical-grade quality for research and formulation development.

Precautions: Individuals with known hypersensitivity to thiamine or its derivatives should avoid supplementation. Pregnant or lactating women and children should consult a healthcare professional before use. The long-term safety of high-dose thiamine derivative supplementation has not been fully established.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

369$/KG

289$/KG